LON:GDR genedrive (GDR) Share Price, News & Analysis GBX 0.26 +0.02 (+8.51%) As of 12:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsBuy This Stock About genedrive Stock (LON:GDR) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get genedrive alerts:Sign Up Key Stats Today's Range 0.21▼ 0.2650-Day Range 0.23▼ 1.2952-Week Range 0.19▼ 3Volume82.02 million shsAverage Volume11.88 million shsMarket Capitalization£2.61 millionP/E RatioN/ADividend Yield1.57%Price TargetN/AConsensus RatingN/A Company Overview ggenedrive plc is a pharmacogenetic testing company developing and commercialising a low cost, rapid, versatile and simple to use point of need pharmacogenetic platform for the diagnosis of genetic variants. This helps clinicians to quickly access key genetic information that will aid them make the right choices over the right medicine or dosage to use for an effective treatment, particularly important in time-critical emergency care healthcare paradigms. Based in the UK, the Company is at the forefront of Point of Care pharmacogenetic testing in emergency healthcare. Pharmacogenetics informs on how your individual genetics impact a medicines ability to work for you. Therefore, by using pharmacogenetics, medicine choices can be personalised, made safer and more effective. The Company has launched its two flagship products, the Genedrive® MT-RNR1 ID Kit and the Genedrive® CYP2C19 ID Kit, both developed and validated in collaboration with NHS partners and deployed on its point of care thermocycler platform. Both tests are single-use disposable cartridges which are ambient temperature stable, circumventing the requirement for cold chain logistics. The Directors believe the Genedrive® MT-RNR1 ID Kit is a worlds-first and allows clinicians to make a decision on antibiotic use in neonatal intensive care units within 26 minutes, ensuring vital care is delivered, avoiding adverse effects potentially otherwise encountered and with no negative impact on the patient care pathway. Its CYP2C19 ID Kit which has no comparably positioned competitor currently allows clinicians to make a decision on the use of Clopidogrel in stroke patients in 70 minutes, ensuring that patients who are unlikely to benefit from or suffer adverse effects from Clopidogrel receive an alternative antiplatelet therapeutic in a timely manner, ultimately improving outcomes. Both tests have undergone review by the National Institute for Health and Care Clinical Excellence ("NICE") and have been recommended for use in the UK NHS. The Company has a clear commercial strategy focused on accelerating growth through maximising in-market sales, geographic and portfolio expansion and strategic M&A, and operates out of its facilities in Manchester. The Company has a clear commercial strategy focused on accelerating growth through maximising in-market sales, geographic and portfolio expansion and strategic M&A, and operates out of its facilities in Manchester. Read More Receive GDR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for genedrive and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. GDR Stock News HeadlinesGenedrive plc Publishes Circular and Announces General MeetingOctober 1, 2025 | msn.comGenedrive Addresses Share Price Movement and Highlights Pilot Study ProgressAugust 14, 2025 | msn.comGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real opportunity isn’t in coins or bullion. In every major gold rally of the past 50 years, there’s been another investment that has delivered dramatically higher returns.October 7 at 2:00 AM | Weiss Ratings (Ad)Genedrive PLCJune 19, 2025 | barrons.comGenedrive Secures Additional Funding for Genomic Testing AdvancementsApril 2, 2025 | msn.comGenedrive Share Chat (GDR)September 17, 2024 | lse.co.ukANGLE plc (DWV.F)September 15, 2024 | finance.yahoo.comTRADING UPDATES: FBD pretax profit falls; Getech's retail offerAugust 9, 2024 | lse.co.ukSee More Headlines GDR Stock Analysis - Frequently Asked Questions How have GDR shares performed this year? genedrive's stock was trading at GBX 2.45 on January 1st, 2025. Since then, GDR shares have decreased by 90.8% and is now trading at GBX 0.23. How were genedrive's earnings last quarter? genedrive plc (LON:GDR) issued its quarterly earnings results on Thursday, March, 27th. The company reported ($0.40) earnings per share (EPS) for the quarter. genedrive had a negative net margin of 1,412.18% and a negative trailing twelve-month return on equity of 191.22%. How do I buy shares of genedrive? Shares of GDR stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of genedrive own? Based on aggregate information from My MarketBeat watchlists, some other companies that genedrive investors own include Rolls-Royce Holdings plc (RR.L), B&M European Value Retail (BME), Coats Group (COA), 4D pharma (DDDD), Greencore Group (GNC), IQE (IQE) and Omega Diagnostics Group (ODX). Company Calendar Last Earnings3/27/2025Today10/07/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Diagnostics & Research Sub-IndustryN/A Current SymbolLON:GDR Previous SymbolLON:EHP CIKN/A Webwww.genedriveplc.com Phone+44-161-9890245FaxN/AEmployees43Year FoundedN/AProfitability EPS (Trailing Twelve Months)GBX (0.02) Trailing P/E RatioN/A Forward P/E Ratio0.00 P/E GrowthN/ANet Income-£21.22 million Net Margins-1,412.18% Pretax MarginN/A Return on Equity-191.22% Return on Assets-74.09% Debt Debt-to-Equity Ratio0.35 Current Ratio4.60 Quick Ratio5.52 Sales & Book Value Annual Sales£676 thousand Price / Sales3.43 Cash FlowGBX 0.11 per share Price / Cash Flow2.00 Book ValueGBX 2.83 per share Price / Book0.08Miscellaneous Outstanding Shares1,024,895,000Free FloatN/AMarket Cap£2.32 million OptionableNot Optionable Beta-0.04 The 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (LON:GDR) was last updated on 10/7/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredU.S. Government Sparking Crypto RallyU.S. Puts GDP on the Blockchain Could this spark the next crypto supercycle? Discover the altcoins poised t...Crypto 101 Media | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding genedrive plc Please log in to your account or sign up in order to add this asset to your watchlist. Share genedrive With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.